Can a gentler steroid dose protect children's kidneys without the harsh side effects?
NCT ID NCT07719140
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial compares two starting doses of the steroid prednisone for children with lupus-related kidney inflammation (lupus nephritis). The standard high dose can cause serious side effects like growth problems and bone thinning. The study asks whether a lower initial dose can control the kidney disease just as well while reducing those harms. About 198 children aged 6 to 17 with confirmed lupus nephritis will be randomly assigned to either a low-dose or high-dose steroid regimen, and their kidney function will be measured after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- prednisone (a corticosteroid) given at either a low or high starting dose
- What this could lead to
- If lower doses work as well as high doses, children with lupus nephritis could avoid severe steroid side effects like stunted growth and bone problems.
- What could go wrong
- This is a Phase 4 trial, but the lower dose might turn out to be less effective at controlling kidney inflammation, risking kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Chidren's Hospital of Chongqing Medical University
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Children's Hospital of Fudan University
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Children's Hospital of Nanjing Medical University
NOT_YET_RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Jilin University
NOT_YET_RECRUITINGChangchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shenzhen Children's Hospital
NOT_YET_RECRUITINGShenzhen, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood traps may reveal lupus kidney treatment success
- A simple blood marker may reveal hidden heart risks in lupus
- Could a diabetes drug shield kidneys in lupus?
- Experimental drug aims to protect kidneys in inflammatory diseases
- Could a diabetes drug shield kidneys from lupus damage?
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial